早期三阴性乳腺癌辅助表柔比星联合环磷酰胺序贯紫杉类联合或不联合卡铂(RJBC 1501):随机III期试验
该III期随机试验纳入786例早期三阴性乳腺癌术后患者,1:1随机接受EC-T或EC-TCb辅助化疗。中位随访4.52年,加用卡铂显著改善无病生存(HR 0.66)、无远处复发生存(HR 0.61)和总生存(HR 0.39),但3-4级血液学毒性增加。
要点
- 加用卡铂显著改善DFS:HR 0.66(95%CI 0.44-0.97;P=0.034)。
- 加用卡铂显著改善DDFS:HR 0.61(95%CI 0.38-0.98;P=0.040)。
- 加用卡铂显著改善OS:HR 0.39(95%CI 0.16-0.94;P=0.029)。
核心结论
- 在早期三阴性乳腺癌辅助EC-T化疗中加入卡铂显著改善DFS、DDFS和OS。
- 尽管观察到血液学毒性增加,但未出现新的安全性信号。
研究设计与样本
- III期随机试验,纳入接受根治性手术的淋巴结阳性或阴性(肿瘤大小≥1.0 cm)三阴性乳腺癌患者。
- 按淋巴结状态分层,1:1随机接受4周期EC序贯4周期T联合或不联合卡铂辅助化疗。
- 主要终点为无病生存(DFS),次要终点包括无远处复发生存(DDFS)、总生存(OS)和安全性。
- 研究有80%把握度检测DFS风险比(HR)为0.64,双侧I类错误为0.05。
- 2016年3月至2023年3月共随机分配786例患者至EC-T组(n=391)或EC-TCb组(n=395)。
主要发现
- 中位随访4.52年(IQR 2.83-6.06),EC-T组和EC-TCb组分别报告62例和41例事件。
- 加用卡铂显著改善DFS:HR 0.66(95%CI 0.44-0.97;P=0.034)。
- 加用卡铂显著改善DDFS:HR 0.61(95%CI 0.38-0.98;P=0.040)。
- 加用卡铂显著改善OS:HR 0.39(95%CI 0.16-0.94;P=0.029)。
- EC-TCb组3-4级不良事件发生率(49.9%)高于EC-T组(38.7%),主要因中性粒细胞减少(47.0% vs 37.8%)和血小板减少(4.5% vs 0%)发生率更高;其他3-4级毒性相当。
临床怎么用
- 作者认为,在早期三阴性乳腺癌辅助EC-T化疗中加入卡铂可显著改善DFS、DDFS和OS。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy and safety of adjuvant epirubicin plus cyclophosphamide followed by taxanes (EC-T) versus EC-T plus carboplatin (EC-TCb) in patients with early-stage triple-negative breast cancer (TNBC). PATIENTS AND METHODS: In this phase III trial, patients with TNBC with node-positive or node-negative (tumor size ≥1.0 cm) disease who received definitive surgery, were stratified by lymph node status and randomly assigned in a 1:1 ratio to receive four cycles of EC followed by four cycles T with or without carboplatin adjuvant chemotherapy. The primary end point was disease-free survival (DFS). Secondary end points included distant DFS (DDFS), overall survival (OS), and safety. This study had 80% power to detect a DFS hazard ratio (HR) of 0.64, with a two-sided type I error of 0.05. RESULTS: A total of 786 patients were randomly assigned to receive EC-T (n = 391) or EC-TCb (n = 395) between March 2016 and March 2023. With a median follow-up of 4.52 (IQR, 2.83-6.06) years, 62 and 41 events were reported in the EC-T and EC-TCb arm, respectively. Adding carboplatin significantly improved DFS (HR, 0.66; [95% CI, 0.44 to 0.97]; P = .034), DDFS (HR, 0.61 [95% CI, 0.38 to 0.98]; P = .040), and OS (HR, 0.39 [95% CI, 0.16 to 0.94]; P = .029). Grade 3 to 4 adverse events were more frequent among the EC-TCb arm (49.9%) than the EC-T arm (38.7%), primarily driven by higher incidence of neutropenia (47.0% v 37.8%) and thrombocytopenia (4.5% v 0%). Other grade 3 to 4 toxicities were comparable. CONCLUSION: Adding carboplatin to adjuvant EC-T chemotherapy significantly improves DFS, DDFS, and OS in patients with early-stage TNBC. Although increased hematologic toxicity was observed, no new safety signals emerged.
引用
- Chen X, Huang J, Shi H, et al. Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial. J Clin Oncol. 2025. PMID: 41365333. doi:10.1200/JCO-25-02412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。